FDA approves GSK’s RSV vaccine for high-risk adults ages 50 to 59, expanding shot’s reach
A view shows GlaxoSmithKline headquarters in London, Britain, January 17, 2022.Hannah Mckay | ReutersThe Food and Drug Administration on Friday ...
A view shows GlaxoSmithKline headquarters in London, Britain, January 17, 2022.Hannah Mckay | ReutersThe Food and Drug Administration on Friday ...
